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INTRODUCTION:
Malaria imposes an unlimited burden
in communities, notably in sub-Saharan
Africa and other equatorial regions (1).
Over time, malaria infections have left
imprints in the human genome that
evolved into single nucleotide polymor-
phisms (SNPs) of genes involved in pro-
tection/susceptibility to malaria (2). The
role of inflammation in malaria patho-
genesis is not well understood (3). 
C-reactive protein (CRP), a nonspecific
acute-phase protein, is a classic marker
for inflammation. CRP is found in
plasma in trace amounts in healthy indi-
viduals, and increases in concentration
100- to 10,000-fold during acute inflam-
mation and in disease situations includ-
ing infections (4,5). CRP is produced
 predominantly by the liver and its pro-
duction is induced by the proinflamma-
tory cytokine interleukin 6 (IL-6) (6,7).
Recent studies suggest that CRP acts
through FcγR to reduce inflammation
and protect against certain autoimmune
diseases (8). Structurally, the CRP has a
sequence homology (shared domains) to
the FcγR binding regions of IgG (9). Fur-
thermore, CRP has high affinity to the
R131-allele product of the FcγRIIa gene
(10), an allele that has been associated
with protection against malaria (11).
Thus, CRP could be a natural competitor
for antimalarial IgG binding to phago-
cytic and other FcγR-containing cells. In-
terestingly, both CRP and FcγR genes are
located on chromosome 1.
Although the pathological role of CRP
in cardiovascular diseases has been thor-
oughly investigated (12), its role in para-
sitic infections, more specifically in ma-
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laria, has been less investigated (13). The
involvement of CRP in human defense
against infection is partially due to its
capacity to bind to phosphorylcholine in
membranes of microorganisms (14,15).
In malaria, the secretion of CRP is in-
duced by proinflammatory cytokines se-
creted by host monocytes/macrophages
(16), and strong correlations have been
found between CRP levels and para-
sitemias (17). Furthermore, apparently
healthy African children were found to
have higher levels of CRP compared
with children in Europe (18) and Papua
New Guinea (13), which might indicate
chronic malarial parasitization of the for-
mer population.
The CRP gene is highly polymorphic,
with SNPs identified at several loci; how-
ever, the trialleleic –286 (C > T > A) SNP
(rs3091244) is strongly associated with
the plasma CRP concentration (19). The
A-allele was found to be associated with
higher basal levels of CRP (20). The dis-
tribution of CRP genotypes and alleles
are geographically and ethnically differ-
ent. Previous studies showed that the
A-allele is more common in African than
in white populations (21), and would
thus be expected to confer a survival ad-
vantage for the inhabitants of malaria en-
demic areas. We examined three SNPs;
–286 C > T > A, –717 T > C and +1444C > T
in material obtained from Daraweesh vil-
lage in eastern Sudan. The –286 SNP was
found to be different in ethnic groups
with varying susceptibility to malaria
(22); thus, it was selected for further
analysis in this study.
MATERIALS AND METHODS
Study Area and Population
This study was carried out in
Daraweesh village (the total population
was >550 individuals in 2005), eastern
Sudan, between 1991 and 2005. The in-
habitants are descendant of the Fulani
tribe from Higher Volta (Burkina Faso) in
West Africa. The ethnicity in Daraweesh
has been maintained by a high rate of in-
termarriage. In Daraweesh, malaria
transmission is seasonal, starts in Sep-
tember, peaks in October or November
and declines in January to a baseline of
few sporadic cases, a pattern that contin-
ues to August. The malaria incidence is
markedly unstable; severe epidemics
occur in flood years, whereas in drought
years malaria cases are almost absent. In
Daraweesh more than 98% of the malaria
infections were due to Plasmodium falci-
parum. An individual in the village is un-
likely to experience more than one ma-
laria episode in the same season (23,24).
Study Design
The Daraweesh project was a total
population longitudinal study begun in
1991, aiming to document seasonal inci-
dence of malaria in the village, with a co-
hort-based component for study of the
natural immune response to malaria. The
study design has been thoroughly de-
scribed (23,25). Malaria infection was
documented by active and passive sur-
veillances during the malaria season.
Data used in this study were obtained
over a 9-year period between 1991 and
2005. This study used longitudinally col-
lected data for 3 parameters: the number
of malaria episodes, the parasite density
and the temperature. For consistency in
execution and method, we used the para-
site density data obtained in the period
between 1993–1996, when the density
was scored semiquantitatively (+, + +, 
+ + + and + + + + ) and in 1998–1999,
when parasite count was used. However,
during both periods heavy malaria trans-
mission occurred in the area. The plasma
samples used in this study were obtained
in May 2005 from 192 donors. All donors
had no malaria infection at the time of
sampling, demonstrated by polymerase
chain reaction (PCR) analysis of the sam-
ples. The number, age and sex of the pa-
tients are shown in Table 1.
Longitudinal Clinical and
Parasitological Data
Clinical examination and malaria di-
agnosis. Malaria was defined as fever
with measurable temperature of ≥37.5°C
or a recent history of fever and micro-
scopically detectable asexual P. falci-
parum parasitemia of any count. Individ-
uals complaining of fever or symptoms
suggestive for malaria were clinically ex-
amined, then oral temperature (in young
children axillary temperature) and body
weight were measured; thereafter, a
blood smear was taken. Thin and thick
blood films were stained with Giemsa
and examined microscopically for detec-
tion of both sexual and asexual stages of
P. falciparum parasites, using the WHO
standard procedure (26). Slides were
read and revised by expert microscopists
using light microscopy. Malaria patients
were mostly treated with chloroquine
alone (10-10-5 mg/kg/day, over 3 d);
however, in the last two malaria seasons,
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Table 1. The frequencies of the CRP –286 (C > T > A) genotypes carriers, characterization
of the genotype carriers and association of the genotypes with the frequency of malaria
episodes over 9 years of follow-up in Daraweesh village.
Age in years Proportions Malaria 
Frequency in 2005 Sex, of episodes 
CRP genotype (n) (median, 25–75%) M/F Hb AS (n) (median, 25–75%)
AA 0.052 (10) 27.0 (11.0–43.0) 1/9 10.0% (1) 1.5 (0.0–2.00)
AC 0.193 (37) 24.0 (12.8–46.8) 12/25 16.2% (6) 2.0 (1.00–3.00)
AT 0.125 (24) 19.5 (13.5–36.5) 7/17 20.8% (5) 2.0 (1.00–3.00)
CC 0.302 (58) 21.5 (13.0–32.0) 19/39 19.0% (11) 1.0 (0.00–2.00)
CT 0.245 (47) 16.0 (9.3–29.8) 23/24 17.0% (8) 1.0 (0.00–2.00)
TT 0.083 (16) 17.0 (11.0–23.5) 5/11 12.5% (2) 2.0 (0.00–2.00)
Total (192) 19.0 (12.0–34.5) 67/125 17.2 (33) 1.5 (0.00–2.50)
Range 6–78 0–7
P values P = 0.382a P = 0.964b P = 0.076a
aKruskal–Wallis one-way analysis of variance on ranks.
bChi-square test.
in addition to chloroquine, dihydroar-
timisinin and sulphadoxine/
pyrimethamine were used. For clinical
and parasitological follow-up, passive
and active surveillances were carried out
and the overall morbidity and mortality
during the study period were docu-
mented as previously described (23,25).
Individuals in Daraweesh are less likely
to develop more than one malaria
episode in the season, because only <8%
of the recrudescent parasites show new
genotypes (24). Chemoprophylaxis and
bed-nets were not used in the village.
The consent of the village leaders was
obtained and individual informed con-
sent was obtained from donors or par-
ents. The finger prick and venous blood
sample donation were entirely voluntary;
however, for young children the consent
was sought from the parents/guardians.
Ethical permission for the study was
granted by the ethics committees of the
University of Khartoum and Ministry of
Health, Sudan, and national clearance
from the Sudanese Ministry of Health
was obtained.
Blood Samples
Blood samples (3 mL collected in
EDTA-coated vacutainers) were obtained
from 192 donors. The donors included
most of the villagers who were available
at the time of the survey. The sampling
was done before the malaria transmis-
sion season, in May 2005, at a time when
all donors were asymptomatic and their
blood smears were negative for malaria
parasite. The blood was centrifuged for
15 min at 250g, and the buffy coat was
separated and stored at –20°C.
DNA Preparation
DNA was extracted from blood with
Chelex-100. Briefly, around 25 μL of pe-
ripheral blood was incubated at 4°C in 
1 mL of 0.5% Saponin in phosphate-
buffered saline overnight, and then
washed in 1 mL phosphate-buffered
saline at 4°C for 15–30 min. The pellets
were boiled in 200 μL of 5% Chelex-100
in water for 15 min, and after centrifu-
gation at 8,000g for 3 min the DNA was
collected in supernatants and stored at
–20°C.
CRP Genotyping with Pyrosequencing
The –286 C > T > A CRP polymor-
phism (rs3091244) was analyzed by the
pyrosequencing method (22). PCR
primers were designed to amplify the
–286 C > T > A polymorphism, using the
forward and reverse primer (MWG-
Biotech AG, Ebersberg, Germany). The
PCR amplification was performed in a
40-μL reaction using 8 μL of genomic
DNA, 20 μL iProof™ High-Fidelity Mas-
ter Mix (BIO-RAD Laboratories, Her-
cules, CA, USA), and 1.5 μL of each
primer (10 pmol/μL). The PCR was car-
ried out in an Eppendorf Mastercycler®
(Eppendorf AG, Hamburg, Germany)
using a 30-s denaturation at 98°C fol-
lowed by 35 cycles with 98°C for 10 s,
59°C for 20 s and 72°C for 15 s. The final
extension was at 72°C for 5 min. The se-
quencing primer was 5′-GTG CAC CCA
GAT GGC-3′ (MWG-Biotech AG), and
the nucleotide dispensation order was
GCACGTACAGT. Sequencing was car-
ried out as instructed by the protocol
using the PSQTM 96MA pyrosequencing
apparatus.
Statistical Analysis
Sigma Stat software was used for data
analysis. Kruskal–Wallis one-way analy-
sis of variance on ranks was used for
comparison of age, parasite count and
number of malaria episodes between the
different CRP –286 allele/genotype carri-
ers. Proportions and rates were tested by
Chi-square test or Fisher exact test and
correlations were performed by using
Pearson product moment correlation.
RESULTS
Longitudinal Clinical Data
The age of the donors ranged between
6 and 78 years, with a median (25–75%)
age of 19 (12–34.5 years) at the time of
blood sampling in May 2005. There were
no significant age differences between
the carriers of the different CRP –286
genotypes (P = 0.382, Kruskal–Wallis
one-way analysis of variance on ranks).
Although females predominated in this
study (male/female ratio 67:125), the sex
ratios were comparable between the
groups. The number of malaria episodes
experienced by each individual over the
study duration was not correlated with
the donor age at the time of sampling
(r = –0.103, P = 0.154). However, when
the analysis was limited to individuals
born at least 1 year before the beginning
of the study in 1991, there was an in-
verse relationship between age (year of
birth) and number of malaria episodes
(r = –0.266, P = 0.003, n = 121), that is,
older individuals had a lower number of
malaria episodes.
Selection of SNP for Analysis in the
CRP Gene
There are several SNPs in the CRP
gene that could be investigated. How-
ever, in a previous study, at least 30 SNPs
were identified, 9 of which were found
to correlate with plasma CRP levels, but
there was strong linkage disequilibrium
between these SNPs. With stepwise se-
lection, the trialleleic (C > T > A) SNP
–286 (rs3091244) remained strongly asso-
ciated with plasma CRP concentration,
independent of other polymorphisms
(19). In our previous study, we examined
the –286 SNP in addition to another two
polymorphisms, –717 T > C (rs2794521)
and +1444C > T (rs1130864). Because the
prevalence of –286 SNP, unlike that of
the latter two polymorphisms, was sig-
nificantly different in sympatric ethnic
groups with varying susceptibility to ma-
laria in Sudan (22), this SNP was selected
for further analysis.
The CRP –286 Genotypes and
Frequency of Malaria Episodes
The frequencies of the six CRP geno-
types (AA, AC, AT, CT, CC and TT) in
Daraweesh are shown in Table 1. The
lowest and highest frequencies were AA,
0.052 (n = 10) and CC, 0.302 (n = 58), re-
spectively. The number of malaria epi-
sodes (median, 25–75%) experienced by
the carriers of the above genotypes were
comparable, P = 0.076, (Table 1).
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CRP –286 C- > T- > A-Alleles and
Frequency of Malaria Episodes
The frequencies of CRP –286 alleles in
decreasing order were; C-allele (52.08%),
T-allele (26.8%) and A-allele (21.1%).
During the 9 years of study, comparison
of the number of malaria episodes (me-
dian, 25–75%) between A-allele carriers,
(n = 71) 2, 1–3, and non–A-allele carriers
(n = 121) 1, 0–2, showed that the differ-
ence was strongly statistically significant
(P = 0.007) (Figure 1). The number of
 malaria episodes was comparable be-
tween the C-allele (n = 50) 2, 1–3 and
non–C-allele carriers (n = 142) 1, 0–2, 
P = 0.205. Similarly, between the T-allele
(n = 87) 2, 0–3.0 and non–T-allele carriers
(n = 105) 1, 0–2, P = 0.688. Although only
18.2% (10 of 55) of the patients who did
not develop malaria during the follow-
up were A-allele carriers, 63% (5 of 8) of
the donors who had experienced the
highest number of malaria episodes 
(≥5 episodes) were A-allele carriers.
 Approximately 43% (56 of 129) of the
donors who had experienced between 1
to 4 malaria episodes were A-allele carri-
ers (Figure 2). The overall differences in
the proportions between the A- and
non–A-allele carriers in all ranks of infec-
tions (0 to ≥5 episodes) were significant,
P < 0.002.
CRP Genotypes/Alleles, Parasite
Density and Oral Temperature
The parasite count (malaria seasons
1998–1999 [n = 140]) did not differ be-
tween the carriers of the different CRP
genotypes (P = 0.384), but there were sta-
tistically significant higher parasite
counts among A-allele carriers (n = 65)
(2460.0, 455.5–9680.8 parasites/μL of
blood [median, 25–75%]) compared with
the non–A-allele carriers (n = 75) (983.0,
244.8–4950.0), P = 0.039. The parasite
counts were comparable between the 
C-allele carriers and non–C-allele carriers
(P = 0.898) and between the T-allele carri-
ers and non–T-allele carriers (P = 0.279)
(Figure 3). However, using the semiquan-
titative parasite density scoring (malaria
seasons 1993–1996), we found no signifi-
cant differences between the CRP pheno-
ture between the different CRP –286 phe-
notypes/allele carriers (data not shown).
There was no association between the
parasite count and oral temperature (r =
–0.0008, P = 0.992 [n = 171]), although
there was a positive correlation between
the oral temperature and the semiquanti-
tative scoring of parasite density (r =
0.279, P < 0.001 [n = 360]).
Number of Malaria Episodes and
Distribution of CRP Genotypes/Alleles
between Carriers and Noncarriers of
Sickle Hemoglobin
The sickle hemoglobin (Hb AS) carri-
ers (n = 33) experienced a similar num-
ber of malaria episodes ([median,
25–75%] 2.0, 0.0–2.25) as the Hb AA car-
riers (1.0, 0.0–2.75 [n = 159]), P = 0.944,
even when the analysis was limited to
individuals born before the year 1991 
(P = 0.834). Although only one of the AA
genotype carriers (10%, 1 of 10) was a
carrier of Hb AS, the proportions of the
latter among the other CRP genotype
carriers were not significantly different
(range 12.5–20.8%), P = 0.964. The fre-
quency of the Hb AS trait was compara-
ble between the CRP –286 A-allele
(16.9%, 12/59) and non–A-allele (17.3%,
21/100) carriers (P = 0.906); similarly, 
Hb AS was not associated with C- or 
T-alleles (data not shown).
DISCUSSION
The overwhelming effect of malaria on
man over history has imposed evolution-
ary alterations of the human genome
(27), particularly of genes involved in de-
fense mechanisms, to decrease the dis-
ease burden. In this study, we found that
the CRP –286 A-allele was associated
with remarkably increased susceptibility
of the Sudanese donors to malaria. This
could be one reason for the low preva-
lence of the A-allele in this area. The CRP
–286 A-allele influence on malaria sus-
ceptibility in this cohort was stronger
than the effect of Hb AS, the latter
known to be associated with reduced
malaria burden. Furthermore, although
A-allele carriers account for only 18% of
the malaria-resistant individuals (not
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Figure 1. The median number (25–75%) of
seasonal malaria episodes experienced by
Daraweesh inhabitants during 9 years of
surveillance. Comparisons were set be-
tween the CRP –286 C-allele (A), T-allele (B)
and A-allele (C) carriers and the noncarri-
ers of corresponding alleles. There was a
strongly significant difference in the number
of malaria episodes between the A-allele
carriers and the non–A-allele carriers (P =
0.007), but not between the pairs of carriers
and noncarriers of the other two alleles.
type carriers (n = 156) (P = 0.310), or be-
tween C-, T-, or A-allele carriers and the
corresponding noncarriers (P = 0.612, P =
0.580, P = 0.395, respectively). Similarly,
there were no differences in oral tempera-
known to have had malaria in 9 years),
they accounted for 63% of the most sus-
ceptible individuals in the village. This
might be the first report that strongly in-
dicates a role for a CRP polymorphism
and probably of inflammation in malaria
susceptibility. However, the effect of the
CRP on susceptibility to malaria might
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be equally due to modulation of immu-
nity, independently of inflammation.
The dual role of host immunity in pro-
tection from as well as in pathogenesis of
malaria is known (28). In contrast, the
role of inflammation in malaria protec-
tion and pathogenesis is not well defined.
The implication of plasma CRP levels and
inflammation in pregnancy-associated
anemia in the tropics has been reported
(29), otherwise the literature lacks data
relating inflammation or CRP with ma-
laria pathogenesis. Unlike acquired im-
munity, inflammation is a nonspecific re-
sponse to different diseases and there are
no specific units for measurement of in-
flammation. However, CRP is one of the
best markers for inflammation (6). Poly-
morphisms in the promoter region of the
CRP gene (–286 C > T > A) affect the
plasma CRP level, and the A-allele has
been found to be associated with high
CRP concentrations (19, 20).
In this study, the A-allele compared
with the non–A-allele carriers had the
tendency to have higher parasite density
when they developed a new malaria at-
tack or upon recrudescence of para-
sitemia. The association of CRP level
with malaria infection has been previ-
ously reported (17,18,30). However, the
unique observation in this study is that
the association of the A-allele with para-
sitemia was based on several infections
in the same individual and included the
parasite density following treatment fail-
ure. There was no association, however,
between the CRP genotypes/alleles or
the parasite density and body tempera-
ture. This result is in line with our obser-
vation that high parasitemia does not al-
ways parallel malaria symptoms,
including fever.
Taken together, the above findings are
suggestive of a strong association be-
tween CRP and susceptibility to ma-
laria. Possible explanations for this asso-
ciation are (a) inflammation constitutes
part of malaria pathogenesis and CRP
plays a role in the inflammatory pro-
cess; (b) CRP modulates host humoral
immunity (it has been suggested that
CRP binds FcγR in immune cells,
Figure 2. Proportion of A-allele carriers (18%, 43% and 63%) among donors reported to
have had no malaria episode (no attack), 1–4 malaria episodes (1–4 attacks) or 5–7 epi-
sodes (≥5 attacks), respectively. The number of the malaria episodes was based on 9 years
of surveillances in Daraweesh village. The differences in the proportions of the A-allele be-
tween the three groups was significant, P = 0.002, Chi-square test.
Figure 3. As shown in this figure, there were no significant differences in the parasite
counts (in acute and recrudescent infections taken together) between carriers of the dif-
ferent CRP –286 genotypes, AA, AC, AT, CC, CT and TT, in Daraweesh (malaria seasons
1998 and 1999), P = 0.384. However, the parasite count was significantly higher among the
A-allele carriers compared with the non–A-allele carriers (P = 0.039), but there were no
significant differences between the C- and T-allele carriers compared with the non–C-
and non–T-allele carriers, respectively. The break in the x-axis separates the genotypes
from the alleles of the CRP gene.
thereby interfering with the immune re-
sponse to the malaria parasite by in-
hibiting the binding of malaria-specific
IgG antibodies [9]) or (c) CRP modu-
lates the host cellular immunity by al-
tering the proinflammatory (IL-6)/
 antiinflammatory (IL-10) cytokine bal-
ance (16). These effects are not mutually
exclusive, however, and are mediated
by structurally normal CRP, that is, the
SNP is in the noncoding promoter se-
quence. Thus, what matters is the
plasma CRP level, regardless of the
causative polymorphism. Additional ev-
idence for the role of CRP in malaria
susceptibility was our finding that the
A-allele is less frequent in the Fulani
ethnic group compared with the neigh-
boring sympatric tribes (22). The Fulani
are known to be relatively less suscepti-
ble to malaria than their neighbors in
different countries in West Africa
(31,32). The Daraweesh Fulani are origi-
nally from Burkina Faso, in West Africa.
Interestingly, the CRP –286 A-allele
but not the AA genotype was associated
with increased malaria susceptibility, a
situation similar to the role of sickle he-
moglobin, for which the Hb AS but not
the Hb SS genotype is associated with
protection from malaria (33). That situa-
tion may be explained by the fact that
mutations/polymorphisms are devel-
oped to overcome certain risks, but the
same mutations might incur a fitness
cost in the host. Thus, when both alleles
are affected the cost might outweigh the
benefit. Furthermore, we found no dif-
ference in the number of malaria epi-
sodes experienced by the Hb AA and Hb
AS carriers and the distribution of Hb
AS was not different between the differ-
ent CRP –286 genotypes/allele carriers.
However, the number of Hb AS carriers
was small in this study. Similar studies
should be performed to investigate dif-
ferent endemic settings and other func-
tional noncoding and structural coding
CRP gene mutations.
In conclusion, in this longitudinal
 cohort-based study in Daraweesh, we
found a strong association between in-
creased malaria susceptibility and CRP
–286 A-allele carriage. In addition, 
A-allele carriers had significantly higher
parasitemia compared with non–A-allele
carriers. Consequently, these data sug-
gest a strong association between inflam-
mation and malaria pathogenesis, an as-
sociation that is greater than previously
described.
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